---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-14T14:34:13.797600'
end_time: '2026-02-14T14:41:48.272750'
duration_seconds: 454.48
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: SMAD3
  gene_symbol: SMAD3
  uniprot_accession: P84022
  protein_description: 'RecName: Full=SMAD family member 3 {ECO:0000312|HGNC:HGNC:6769};
    Short=SMAD 3 {ECO:0000305}; Short=hSMAD3; AltName: Full=JV15-2; AltName: Full=Mothers
    against decapentaplegic homolog 3; Short=MAD homolog 3; Short=Mad3; Short=Mothers
    against DPP homolog 3; Short=hMAD-3;'
  gene_info: Name=SMAD3 {ECO:0000312|HGNC:HGNC:6769}; Synonyms=MADH3;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the dwarfin/SMAD family. .
  protein_domains: Dwarfin. (IPR013790); MAD_homology1_Dwarfin-type. (IPR003619);
    MAD_homology_MH1. (IPR013019); SMAD-like_dom_sf. (IPR017855); SMAD_dom_Dwarfin-type.
    (IPR001132)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 26
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P84022
- **Protein Description:** RecName: Full=SMAD family member 3 {ECO:0000312|HGNC:HGNC:6769}; Short=SMAD 3 {ECO:0000305}; Short=hSMAD3; AltName: Full=JV15-2; AltName: Full=Mothers against decapentaplegic homolog 3; Short=MAD homolog 3; Short=Mad3; Short=Mothers against DPP homolog 3; Short=hMAD-3;
- **Gene Information:** Name=SMAD3 {ECO:0000312|HGNC:HGNC:6769}; Synonyms=MADH3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the dwarfin/SMAD family. .
- **Key Domains:** Dwarfin. (IPR013790); MAD_homology1_Dwarfin-type. (IPR003619); MAD_homology_MH1. (IPR013019); SMAD-like_dom_sf. (IPR017855); SMAD_dom_Dwarfin-type. (IPR001132)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SMAD3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SMAD3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SMAD3** (gene ID: SMAD3, UniProt: P84022) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P84022
- **Protein Description:** RecName: Full=SMAD family member 3 {ECO:0000312|HGNC:HGNC:6769}; Short=SMAD 3 {ECO:0000305}; Short=hSMAD3; AltName: Full=JV15-2; AltName: Full=Mothers against decapentaplegic homolog 3; Short=MAD homolog 3; Short=Mad3; Short=Mothers against DPP homolog 3; Short=hMAD-3;
- **Gene Information:** Name=SMAD3 {ECO:0000312|HGNC:HGNC:6769}; Synonyms=MADH3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the dwarfin/SMAD family. .
- **Key Domains:** Dwarfin. (IPR013790); MAD_homology1_Dwarfin-type. (IPR003619); MAD_homology_MH1. (IPR013019); SMAD-like_dom_sf. (IPR017855); SMAD_dom_Dwarfin-type. (IPR001132)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SMAD3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SMAD3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SMAD3** (gene ID: SMAD3, UniProt: P84022) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Title: Functional annotation of human SMAD3 (UniProt P84022)

Plan and verification. We verified the target as human SMAD3, a receptor-regulated SMAD (R‑SMAD) in the dwarfin/SMAD family. SMAD3 comprises an N‑terminal MH1 DNA‑binding domain, a C‑terminal MH2 protein‑interaction domain, and a regulatory linker; this architecture underlies its role as a transcriptional effector of TGF‑β/Activin signaling (wang2023smadproteinsin pages 1-2, danielpour2024advancesandchallenges pages 12-13). Below we synthesize current evidence with emphasis on 2023–2025 sources and translational applications.

Key concepts and definitions. SMAD3 is the principal R‑SMAD that, upon activation by TGF‑β type I receptor (TGFBR1/ALK5), forms oligomers with the co‑SMAD, SMAD4, to regulate target genes. The MH1 domain binds short Smad‑binding elements (SBE, 5′‑GTCT/AGAC‑3′) and CAGA‑box variants, whereas MH2 mediates receptor docking, SMAD4 assembly, and cofactor recruitment; the linker integrates regulatory post‑translational modifications (PTMs) (wang2023smadproteinsin pages 1-2, danielpour2024advancesandchallenges pages 12-13). Because Smad core motifs are only 4 bp, SMAD3 complexes have intrinsically low DNA affinity and rely on cooperating transcription factors (e.g., AP‑1) and composite motifs to achieve specificity (itoh2024analysisofthe pages 1-2).

Recent mechanistic developments (2023–2025 priority). New analyses emphasize DNA recognition and context dependence. CASTing of endogenous Smad2/3–Smad4 complexes across cell types showed differential preference for SBE vs CAGA and frequent enrichment of Fos/Jun motifs; composite elements were required for robust TGF‑β responses, explaining cell‑type dependence (The FASEB Journal, 2024; https://doi.org/10.1096/fj.202400978r) (itoh2024analysisofthe pages 1-2). Reviews in 2024 synthesized PTM logic: ALK5 phosphorylates the SMAD3 C‑terminal SSXS motif to enable trimerization with SMAD4 and nuclear import; linker phosphorylation by ERK/MAPK and CDK8/9 tunes transcriptional output and cofactor engagement, while PPM1A dephosphorylation and RanBP3 export terminate signaling (Pharmaceuticals, 2024; https://doi.org/10.3390/ph17040533; Pharmaceuticals, 2024; https://doi.org/10.3390/ph17030326) (danielpour2024advancesandchallenges pages 12-13, runa2024targetingsmaddependentsignaling pages 2-4, runa2024targetingsmaddependentsignaling pages 8-9). Single‑cell work highlighted distinct SMAD3 dynamics, including often higher basal nuclear localization than SMAD2 and non‑redundant ligand responses, reinforcing differential roles within the Smad2/3 pair (2024; https://doi.org/10.26083/tuprints-00028725) (huang2024investigatingsmadsignaling pages 81-84).

Biochemical role and pathway placement. In canonical TGF‑β signaling, ligand‑bound TGFBR2 phosphorylates ALK5, which then phosphorylates SMAD3 at the C‑terminal SSXS motif; phospho‑SMAD3 dissociates, oligomerizes primarily as a heterotrimer with SMAD4, and translocates to the nucleus to regulate transcription with coactivators (e.g., p300/CBP) or corepressors (e.g., TGIF, Ski/Sno) (Pharmaceuticals, 2024; https://doi.org/10.3390/ph17040533) (danielpour2024advancesandchallenges pages 12-13). SMAD3’s linker is a regulatory hub targeted by ERK/MAPK, CDKs and other kinases; phosphatases (PPM1A, SCPs) and E3 ligases (SMURF/NEDD4L) modulate turnover and signal duration (Pharmaceuticals, 2024; https://doi.org/10.3390/ph17030326) (runa2024targetingsmaddependentsignaling pages 8-9). Functionally, SMAD3 contributes to EMT programs and extracellular matrix gene induction; differential DNA‑binding capacity versus SMAD2 (SMAD2’s MH1 insertion restricts direct DNA binding) gives SMAD3 a prominent direct chromatin‑engagement role (danielpour2024advancesandchallenges pages 12-13).

Subcellular localization and dynamics. SMAD3 shuttles constitutively between cytoplasm and nucleus; receptor‑mediated phosphorylation exposes/imports MH1‑encoded NLSs via importin‑β pathways. Export is driven by RanBP3 and exportins when SMAD3 is dephosphorylated by PPM1A; SMAD4 import relies on importin‑α and nuclear pore components participate in flux (Pharmaceuticals, 2024; https://doi.org/10.3390/ph17030326) (runa2024targetingsmaddependentsignaling pages 2-4). Single‑cell studies report that SMAD3 can be constitutively more nuclear than SMAD2 and that its interaction with SMAD4 differs dynamically even when SSXS sites are phosphorylated, contributing to distinct signaling kinetics (2024; https://doi.org/10.26083/tuprints-00028725) (huang2024investigatingsmadsignaling pages 81-84).

Genome binding and enhancer logic. Genome‑wide and CASTing studies show that Smad complexes bind short SBEs/CAGA motifs with low affinity and typically require adjacent TF motifs (e.g., AP‑1) at enhancers to stabilize occupancy and drive transcription, explaining strong context dependence. Reporter assays validated that composite elements potentiate cell type–specific TGF‑β responses (FASEB J, 2024; https://doi.org/10.1096/fj.202400978r) (itoh2024analysisofthe pages 1-2). Methodologically, a multiplexed TR‑FRET uHTS assay now enables simultaneous monitoring of SMAD4–SMAD3 PPI and SBE DNA binding at single‑amino‑acid resolution, and has identified initial small‑molecule hits that disrupt the SMAD4–SMAD3–DNA complex (J Mol Cell Biol, 2023; https://doi.org/10.1093/jmcb/mjad068) (ouyang2023amultiplexedtimeresolved pages 1-2).

Cellular location of function. SMAD3 functions in both cytoplasm (activation and complex assembly) and nucleus (transcriptional regulation). Its transcriptional activity depends on nuclear accumulation with SMAD4 and on engagement of coactivators/corepressors; termination involves nuclear export following dephosphorylation (runa2024targetingsmaddependentsignaling pages 2-4, danielpour2024advancesandchallenges pages 12-13).

Disease relevance and phenotypes. SMAD3 is integral to fibrotic programs and cancer biology via TGF‑β‑driven EMT and matrix deposition; perturbations in TGF‑β/SMAD signaling can support tumor progression and immune evasion, while intact signaling provides tumor‑suppressive effects in early disease—underscoring context‑dependent roles (Diagnostics, 2023; https://doi.org/10.3390/diagnostics13172769) (wang2023smadproteinsin pages 17-19). Inherited defects within the TGF‑β–SMAD axis cause syndromic aortopathy; SMAD3 is the defining gene for Loeys–Dietz syndrome type 3, and its downstream signaling contributes to vascular remodeling and aneurysm risk across the TGF‑β pathway disorders (wang2023smadproteinsin pages 17-19). Expert immuno‑oncology perspectives further highlight TGF‑β’s control of anti‑tumor immunity, with SMAD2/3 as key intracellular mediators (Nature Reviews Immunology, 2023; https://doi.org/10.1038/s41577-022-00796-z) (wang2023smadproteinsin pages 17-19).

Therapeutics and real‑world implementations. Upstream TGF‑β pathway inhibitors include ALK5 small‑molecule inhibitors (e.g., galunisertib/LY2157299; vactosertib/TEW‑7197) and pan‑TGF‑β neutralizing antibodies/ligand traps (e.g., fresolimumab). Reviews in 2024–2025 outline their clinical exploration in oncology and fibrosis and emphasize challenges from pathway pleiotropy (Pharmaceuticals, 2024; https://doi.org/10.3390/ph17040533) (danielpour2024advancesandchallenges pages 12-13). Novel combinatorial strategies include a dual ALK5/VEGFR2 inhibitor (TU2218) that enhances immune‑mediated antitumor effects and synergizes with checkpoint blockade in preclinical models, illustrating rational co‑targeting of TGF‑β/VEGF axes (Cancer Immunol Immunother, 2024; https://doi.org/10.1007/s00262-024-03777-4) (danielpour2024advancesandchallenges pages 12-13). Downstream targeting is emerging: a uHTS TR‑FRET platform directly screens for inhibitors of the SMAD4–SMAD3–DNA complex, identifying initial hit chemotypes and providing a route to modulate nuclear SMAD function selectively (J Mol Cell Biol, 2023; https://doi.org/10.1093/jmcb/mjad068) (ouyang2023amultiplexedtimeresolved pages 1-2). Expert reviews recommend cell‑type– and context‑guided strategies and, where possible, selective interference at SMAD nodes to mitigate systemic toxicity (wang2023smadproteinsin pages 17-19, danielpour2024advancesandchallenges pages 12-13).

Relevant statistics and data highlights. Quantitative DNA‑binding studies show Smad complexes’ low intrinsic affinity for 4‑bp SBE cores (Kd on the order of ~10^−7 M), necessitating cooperative binding at composite motifs; CASTing revealed motif‑usage shifts among A549, HepG2, and HaCaT cells, aligning with changes in Smad complex composition and partner TF availability (FASEB J, 2024; https://doi.org/10.1096/fj.202400978r) (itoh2024analysisofthe pages 1-2). Screening statistics from an FDA‑approved bioactive library using the uHTS TR‑FRET assay yielded tractable hits (gambogic/gambogenic acids), validating feasibility of high‑throughput disruption of SMAD4–SMAD3–DNA assemblies (J Mol Cell Biol, 2023; https://doi.org/10.1093/jmcb/mjad068) (ouyang2023amultiplexedtimeresolved pages 1-2).

Expert analyses and opinions. Contemporary reviews argue that because systemic TGF‑β blockade can impair tissue homeostasis, precise targeting of SMAD‑dependent mechanisms—guided by single‑cell context, enhancer grammar, and PTM state—may produce better therapeutic indices in cancer and fibrosis (Pharmaceuticals, 2024; https://doi.org/10.3390/ph17040533; Diagnostics, 2023; https://doi.org/10.3390/diagnostics13172769) (wang2023smadproteinsin pages 17-19, danielpour2024advancesandchallenges pages 12-13). Immuno‑oncology perspectives underscore integrating TGF‑β/SMAD inhibition with immune checkpoint therapies to reverse exclusion and stromal barriers (Nature Reviews Immunology, 2023; https://doi.org/10.1038/s41577-022-00796-z) (wang2023smadproteinsin pages 17-19).

Primary function and cellular site of action summarized. SMAD3 is a sequence‑specific transcription factor and signal transducer. It is not an enzyme or transporter; rather, it is phosphorylated at its C‑terminal SSXS motif by ALK5, complexes with SMAD4, and regulates gene expression by binding SBE/CAGA‑containing enhancers and promoters with cofactors. Its functional activity occurs in the nucleus following cytoplasmic activation and translocation (runa2024targetingsmaddependentsignaling pages 2-4, danielpour2024advancesandchallenges pages 12-13, itoh2024analysisofthe pages 1-2).

| Aspect | Key facts | Primary sources (authors, year; journal) | URL/DOI |
|---|---|---|---|
| Identity & domains | - Receptor-regulated SMAD (R-SMAD) belonging to the dwarfin/SMAD family<br>- Conserved MH1 (N-term, DNA-binding) and MH2 (C-term, protein interaction) domains; regulatory linker between them | Wang Q. et al., 2023; Diagnostics; Danielpour D., 2024; Pharmaceuticals (wang2023smadproteinsin pages 1-2, danielpour2024advancesandchallenges pages 12-13) | doi:10.3390/diagnostics13172769; https://doi.org/10.3390/ph17040533 |
| Canonical activation | - TGF-βRI/ALK5 phosphorylates the C-terminal SSXS motif on SMAD3<br>- Phosphorylated SMAD3 oligomerizes with SMAD4 and translocates to nucleus; recruitment aided by adaptors (e.g., SARA) | Runa F. et al., 2024; Pharmaceuticals; Danielpour D., 2024; Pharmaceuticals (runa2024targetingsmaddependentsignaling pages 2-4, danielpour2024advancesandchallenges pages 12-13) | 10.3390/ph17030326; https://doi.org/10.3390/ph17040533 |
| DNA recognition | - SMAD3/SMAD4 complexes bind SBE (GTCT/AGAC) and CAGA motifs but have low intrinsic DNA affinity<br>- Require cooperating TFs (e.g., AP-1) and composite motifs for stable, cell-type-specific binding | Itoh Y. et al., 2024; The FASEB Journal; Ouyang W. et al., 2023; J Mol Cell Biol (itoh2024analysisofthe pages 1-2, ouyang2023amultiplexedtimeresolved pages 1-2) | https://doi.org/10.1096/fj.202400978r; https://doi.org/10.1093/jmcb/mjad068 |
| Nuclear shuttling | - Dynamic cytoplasm↔nucleus shuttling mediated by importins/exportins (importin-β/α, RanBP3) and nuclear pores<br>- Termination/export promoted by phosphatase PPM1A (dephosphorylates C-term) | Runa F. et al., 2024; Pharmaceuticals; Huang Z., 2024 (runa2024targetingsmaddependentsignaling pages 2-4, huang2024investigatingsmadsignaling pages 81-84) | 10.3390/ph17030326; https://doi.org/10.26083/tuprints-00028725 |
| Post-translational regulation | - Linker phosphorylation by ERK/MAPK and CDK8/9 modulates transcriptional output<br>- Ubiquitin ligases (SMURF family, NEDD4L, etc.) drive proteasomal turnover; phosphatases (PPM1A, SCPs) reverse phosphorylation | Runa F. et al., 2024; Pharmaceuticals; Danielpour D., 2024; Pharmaceuticals (runa2024targetingsmaddependentsignaling pages 8-9, danielpour2024advancesandchallenges pages 12-13) | 10.3390/ph17030326; https://doi.org/10.3390/ph17040533 |
| Enhancer logic & context dependence | - SMAD complexes often act at distal enhancers and require nearby TF motifs (AP‑1, FOXO1 etc.) to drive context-specific transcription<br>- Genome-wide assays (CASTing/ChIP) reveal cell-type motif preferences and composite-site dependence | Itoh Y. et al., 2024; The FASEB Journal; Ouyang W. et al., 2023; J Mol Cell Biol (itoh2024analysisofthe pages 1-2, ouyang2023amultiplexedtimeresolved pages 1-2) | https://doi.org/10.1096/fj.202400978r; https://doi.org/10.1093/jmcb/mjad068 |
| Disease genetics | - Pathogenic SMAD3/TGF‑β axis variants underlie vascular/connective-tissue phenotypes (Loeys–Dietz–related aortopathy) and contribute to fibrotic and cancer biology<br>- Dysregulated SMAD3 signaling implicated in fibrosis, tumor progression, and immune modulation | Wang Q. et al., 2023; Diagnostics; Danielpour D., 2024; Pharmaceuticals (wang2023smadproteinsin pages 17-19, danielpour2024advancesandchallenges pages 12-13) | doi:10.3390/diagnostics13172769; https://doi.org/10.1186/s12967-024-05411-4 |
| Therapeutic applications | - Upstream inhibitors: ALK5 inhibitors (galunisertib, vactosertib) and pan‑TGF‑β traps (fresolimumab) in clinical/preclinical exploration<br>- Dual-target strategies (e.g., ALK5/VEGFR TU2218) and direct SMAD4–SMAD3–DNA screening (TR‑FRET uHTS) enable downstream/combination approaches | Danielpour D., 2024; Pharmaceuticals; Kim N.-H. et al., 2024; Cancer Immunol Immunother; Ouyang W. et al., 2023; J Mol Cell Biol (danielpour2024advancesandchallenges pages 12-13, ouyang2023amultiplexedtimeresolved pages 1-2) | https://doi.org/10.3390/ph17040533; https://doi.org/10.1007/s00262-024-03777-4; https://doi.org/10.1093/jmcb/mjad068 |


*Table: Compact reference table summarizing SMAD3 identity, mechanism, regulation, genomic binding logic, disease links, and therapeutic strategies with primary 2023–2025 sources (pqac context IDs). This provides a quick evidence‑linked overview for functional annotation and research planning.*

Citations with URLs and dates
- Wang Q. et al., 2023, Diagnostics 13:2769. SMAD proteins in TGF‑β signalling pathway in cancer. https://doi.org/10.3390/diagnostics13172769 (Accessed 2026) (wang2023smadproteinsin pages 1-2, wang2023smadproteinsin pages 17-19).
- Danielpour D., 2024, Pharmaceuticals. Advances and challenges in targeting TGF‑β isoforms. https://doi.org/10.3390/ph17040533 (Accessed 2026) (danielpour2024advancesandchallenges pages 12-13).
- Runa F. et al., 2024, Pharmaceuticals. Targeting SMAD‑dependent signaling. https://doi.org/10.3390/ph17030326 (Accessed 2026) (runa2024targetingsmaddependentsignaling pages 2-4, runa2024targetingsmaddependentsignaling pages 8-9).
- Itoh Y. et al., 2024, The FASEB Journal. DNA‑binding properties of TGF‑β‑activated Smad complexes. https://doi.org/10.1096/fj.202400978r (Accessed 2026) (itoh2024analysisofthe pages 1-2).
- Ouyang W. et al., 2023, Journal of Molecular Cell Biology. TR‑FRET uHTS assay targeting SMAD4–SMAD3–DNA. https://doi.org/10.1093/jmcb/mjad068 (Accessed 2026) (ouyang2023amultiplexedtimeresolved pages 1-2).
- Huang Z., 2024. Investigating SMAD signaling dynamics and function in single cells. https://doi.org/10.26083/tuprints-00028725 (Accessed 2026) (huang2024investigatingsmadsignaling pages 81-84).
- Nixon B.G. et al., 2023, Nature Reviews Immunology. TGFβ control of immune responses in cancer. https://doi.org/10.1038/s41577-022-00796-z (Accessed 2026) (wang2023smadproteinsin pages 17-19).

Limitations. While core mechanistic features are well supported, quantitative PTM kinetics and complete maps of human disease variants specific to SMAD3 were not exhaustively retrieved here; future updates should integrate curated variant databases and clinical genetics cohorts specifically for SMAD3.


References

1. (wang2023smadproteinsin pages 1-2): Qi Wang, Fei Xiong, Guanhua Wu, Da Wang, Wenzheng Liu, Junsheng Chen, Yongqiang Qi, Bing Wang, and Yongjun Chen. Smad proteins in tgf-β signalling pathway in cancer: regulatory mechanisms and clinical applications. Diagnostics, 13:2769, Aug 2023. URL: https://doi.org/10.3390/diagnostics13172769, doi:10.3390/diagnostics13172769. This article has 64 citations and is from a poor quality or predatory journal.

2. (danielpour2024advancesandchallenges pages 12-13): David Danielpour. Advances and challenges in targeting tgf-β isoforms for therapeutic intervention of cancer: a mechanism-based perspective. Pharmaceuticals, Apr 2024. URL: https://doi.org/10.3390/ph17040533, doi:10.3390/ph17040533. This article has 52 citations and is from a poor quality or predatory journal.

3. (itoh2024analysisofthe pages 1-2): Yuka Itoh, Kunio Miyake, Daizo Koinuma, Chiho Omata, Masao Saitoh, and Keiji Miyazawa. Analysis of the dna‐binding properties of tgf‐β‐activated smad complexes unveils a possible molecular basis for cellular context‐dependent signaling. The FASEB Journal, Aug 2024. URL: https://doi.org/10.1096/fj.202400978r, doi:10.1096/fj.202400978r. This article has 2 citations.

4. (runa2024targetingsmaddependentsignaling pages 2-4): Farhana Runa, Gabriela Ortiz-Soto, Natan Roberto de Barros, and Jonathan A. Kelber. Targeting smad-dependent signaling: considerations in epithelial and mesenchymal solid tumors. Pharmaceuticals, 17:326, Mar 2024. URL: https://doi.org/10.3390/ph17030326, doi:10.3390/ph17030326. This article has 17 citations and is from a poor quality or predatory journal.

5. (runa2024targetingsmaddependentsignaling pages 8-9): Farhana Runa, Gabriela Ortiz-Soto, Natan Roberto de Barros, and Jonathan A. Kelber. Targeting smad-dependent signaling: considerations in epithelial and mesenchymal solid tumors. Pharmaceuticals, 17:326, Mar 2024. URL: https://doi.org/10.3390/ph17030326, doi:10.3390/ph17030326. This article has 17 citations and is from a poor quality or predatory journal.

6. (huang2024investigatingsmadsignaling pages 81-84): Zixin Huang. Investigating smad signaling dynamics and function in single cells. Text, Jan 2024. URL: https://doi.org/10.26083/tuprints-00028725, doi:10.26083/tuprints-00028725. This article has 0 citations and is from a peer-reviewed journal.

7. (ouyang2023amultiplexedtimeresolved pages 1-2): Wukun Ouyang, Qianjin Li, Qiankun Niu, Min Qui, Haian Fu, Yuhong Du, and Xiulei Mo. A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting the smad4–smad3–dna complex. Journal of Molecular Cell Biology, Nov 2023. URL: https://doi.org/10.1093/jmcb/mjad068, doi:10.1093/jmcb/mjad068. This article has 11 citations and is from a peer-reviewed journal.

8. (wang2023smadproteinsin pages 17-19): Qi Wang, Fei Xiong, Guanhua Wu, Da Wang, Wenzheng Liu, Junsheng Chen, Yongqiang Qi, Bing Wang, and Yongjun Chen. Smad proteins in tgf-β signalling pathway in cancer: regulatory mechanisms and clinical applications. Diagnostics, 13:2769, Aug 2023. URL: https://doi.org/10.3390/diagnostics13172769, doi:10.3390/diagnostics13172769. This article has 64 citations and is from a poor quality or predatory journal.

## Citations

1. itoh2024analysisofthe pages 1-2
2. huang2024investigatingsmadsignaling pages 81-84
3. danielpour2024advancesandchallenges pages 12-13
4. runa2024targetingsmaddependentsignaling pages 8-9
5. runa2024targetingsmaddependentsignaling pages 2-4
6. ouyang2023amultiplexedtimeresolved pages 1-2
7. wang2023smadproteinsin pages 17-19
8. wang2023smadproteinsin pages 1-2
9. https://doi.org/10.1096/fj.202400978r
10. https://doi.org/10.3390/ph17040533;
11. https://doi.org/10.3390/ph17030326
12. https://doi.org/10.26083/tuprints-00028725
13. https://doi.org/10.3390/ph17040533
14. https://doi.org/10.1093/jmcb/mjad068
15. https://doi.org/10.3390/diagnostics13172769
16. https://doi.org/10.1038/s41577-022-00796-z
17. https://doi.org/10.1007/s00262-024-03777-4
18. https://doi.org/10.1096/fj.202400978r;
19. https://doi.org/10.1186/s12967-024-05411-4
20. https://doi.org/10.1007/s00262-024-03777-4;
21. https://doi.org/10.3390/diagnostics13172769,
22. https://doi.org/10.3390/ph17040533,
23. https://doi.org/10.1096/fj.202400978r,
24. https://doi.org/10.3390/ph17030326,
25. https://doi.org/10.26083/tuprints-00028725,
26. https://doi.org/10.1093/jmcb/mjad068,